4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages 457-463

  Hoskin, Peter J ^a   Kirkwood, Amy A ^b   Popova, Bilyana ^b   Smith, Paul ^b   Robinson, Martin ^c   Gallop Evans, Eve ^d   Coltart, Stewart ^e   Illidge, Timothy ^f   Madhavan, Krishnaswamy ^g   Brammer, Caroline ^h   Diez, Patricia ^a   Jack, Andrew ⁱ   Syndikus, Isabel ^j  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c WESTON PARK HOSPITAL   (United Kingdom)

^d VELINDRE CANCER CENTRE   (United Kingdom)

^e KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^h NEW CROSS HOSPITAL   (United Kingdom)

ⁱ LEEDS GENERAL INFIRMARY   (United Kingdom)

^j CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERY ELDERLY; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PALLIATIVE CARE; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897456841     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70036-1     Document Type: Article

References (10)

1. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011, 100:86-92.
2. Choi NC, Timothy AR, Sheldon SD, Carey RW, Aisenberg AC Low dose fractionated total body irradiation in the treatment of advanced non Hodgkins lymphoma. Cancer 1979, 5:165-169.
3. Ganem G, Lambin P, Socié G, et al. Potential role for low dose limited-field radiation therapy (2 × 2 grays) in advanced low-grade non-Hodgkin's lymphomas. Hematol Oncol 1994, 12:1-8.
4. Ganem G, Cartron G, Girinsky T, Haas RLM, Cosset JM, Solal-Celigny P Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys 2010, 78:975-982.
5. Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003, 21:2474-2480.
6. Evans S, Day S, Royston P Minimisation programme for allocating patients to treatments in clinical trials 1995, Department of Clinical Epidemiology, The London Hospital Medical College, London.
7. Schoenfeld D Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika 1980, 67:145-153.
8. Knoops L, de Jong D The role of the p53 pathway in the treatment of follicular lymphoma. Cell Cycle 2008, 7:436-439.
9. Knoops L, Haas R, de Kemp S, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007, 110:1116-1122.
10. Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res (Tokyo) 2006, 47:183-196.